Tadataka Yamada, M.D., Chief Medical & Scientific Officer of Takeda
TAKEDA US CHICAGO OFFICE
TAKEDA PIPELINE SEE LINKS BELOW
1 https://www.takeda.com/investor-information/annual/files/ar2013_10_en.pdf
2. http://www.takeda.com/research/files/pipeline_20131031_en.pdf
3 http://www.takeda.com/research/pipeline/
2012 Download Entire File PDF 0.4MB 34P
R&D Pipeline (As of October 31, 2013)
PDF 1.0MB 18P
Takeda’s top executives had frequently pointed to TAK-875 as one of their best shots at coming up with an important new approach to treating diabetes. The drug is designed to spur insulin secretion in the pancreas and Takeda had confidently projected an approval in Japan in 2015 with a follow-up approval in the big U.S. market a year or two later.
The termination of the high-profile program caused some anxiety among investors. Takeda’s shares plunged 8% on the loss as analysts wondered how the pharma company could counter the loss of Actos, a $3.7 billion drug that accounted for about a quarter of its revenue in 2011.
Takeda won an approval on a trio of DPP-4 diabetes drugs–Nesina (alogliptin) and two combos with alogliptin, dubbed Oseni and Kazano–at the beginning of the year. But Takeda suffered some big delays in gaining acceptance, a common fate in this field, where regulators are particularly cautious about new drugs. And Merck had already solidified its lead in the DPP-4 market with Januvia whileOnglyza trailed closely behind it. Takeda had hoped that a combination of TAK-875 and Januvia could help regain some lost market territory–but that dream has clearly vanished as well.
January 27, 2014
Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone – a New Atypical Antipsychotic Medication for Adults with Schizophrenia
January 22, 2014
Brintellix® (vortioxetine) for the treatment of major depressive disorder in adults is now available in U.S. pharmacies
January 17, 2014
Takeda Announces the New Drug Application Approval of ADCETRIS® (brentuximab vedotin) in Japan for the Treatment of Malignant Lymphoma
January 14, 2014
Takeda Announces Varicella Vaccine Sales Agreement with the Research Foundation for Microbial Diseases of Osaka University in Japan
January 10, 2014
Notice Concerning the Determination of Terms of Stock Options (Stock Acquisition Rights) for Corporate Officers and Senior Management
2013
December 27, 2013
Takeda Announces Termination of Fasiglifam (TAK-875) Development
December 25, 2013
Takeda Submits a New Drug Application for Fomepizole in Japan for the Treatment of Ethylene Glycol and Methanol Poisonings
December 25, 2013
Takeda Announces Extension of FDA PDUFA Action Date for Vedolizumab
for Ulcerative Colitis
December 24, 2013
Collaboration with Medicines for Malaria Venture
Through Global Health Innovative Technology Fund
December 20, 2013
Takeda Announces the Appointment of New Senior Leadership and Organizational Change
December 20, 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
December 19, 2013
Notice Concerning Stock Options (Stock Acquisition Rights) for Corporate Officers and Senior Management
December 10, 2013
FDA Advisory Committee Recommends Approval of
Takeda’s Investigational Biologic Vedolizumab
December 10, 2013
Takeda Announces Appointment of New Senior Leadership
December 10, 2013
Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
December 10, 2013
Updated Data with Oral Proteasome Inhibitor MLN9708 Reported in Newly Diagnosed Multiple Myeloma Patients
December 9, 2013
Analysis Suggests Increased Overall Survival with Use of Higher Cumulative Dose of VELCADE® (bortezomib) in Patients with Previously Untreated Multiple Myeloma
December 5, 2013
Takeda Announces the Appointment of New Senior Leadership
December 4, 2013
Teva and Takeda Announce Agreement
for Glatiramer Acetate for Multiple Sclerosis Treatment in Japan
November 30, 2013
Takeda Appoints Chief Operating Officer
November 21, 2013
Takeda Announces the Appointment of New Senior Leadership
November 19, 2013
Oral Proteasome Inhibitor MLN9708 Enters into Phase 3 Clinical Study in Japan
November 14, 2013
Takeda to Aid Philippines Typhoon Relief Efforts
November 12, 2013
Takeda Announces Appointment of New Senior Leadership
November 12, 2013
Takeda Announces 118 Abstracts on VELCADE®(bortezomib),ADCETRIS® (brentuximab vedotin) and Leading Pipeline Compounds to be Presented at 55th American Society of Hematology Annual Meeting
October 21, 2013
Takeda Announces Appointment of
New Senior Leadership and Organizational Change
October 7, 2013
Takeda Highlights Data from Clinical Trial of Investigational Norovirus Vaccine Candidate
October 2, 2013
Tri-Institutional Therapeutics Discovery Institute, Inc. Launched by Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College, and Partnership Formed with Takeda Pioneering Collaboration with Research-Based Global Pharmaceutical Company to Conduct Early-Stage Drug Discovery
October 1, 2013
Takeda and Lundbeck Announce FDA Approval of BrintellixTM(vortioxetine) for Treatment of Adults with Major Depressive Disorder
September 26, 2013
Takeda Submits New Drug Application in Japan for TAK-816, aHaemophilus Influenzae type b (Hib) vaccine ~ Expands its commitment to the health of Japanese children~
September 26, 2013
Takeda has been selected for the fourth consecutive yearfor Dow Jones Sustainability Asia Pacific Index
September 24, 2013
Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies, VipidiaTM (alogliptin) and Fixed-Dose Combinations VipdometTM (alogliptin and metformin) andIncresyncTM (alogliptin and pioglitazone)
September 20, 2013
Norgine and Takeda Announce the New Drug Application Approval of OBLEAN® Tablets 120mg in Japan for the Treatment of Obesity with Complications
September 20, 2013
Takeda Announces the Appointment of New Senior Leadership
September 13, 2013
Approval of Partial Changes of Indication of Glufast® in Japan
September 13, 2013
Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR
September 5, 2013
Takeda’s New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
September 2, 2013
Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Cardiovascular Events
August 27, 2013
Takeda Announces Appointment of New Senior Leadership
August 27, 2013
Takeda Announces Appointment of Chief Financial Officer
New Position Integrates Global Finance Functions
August 27, 2013
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer’s Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
August 22, 2013
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease
August 13, 2013
DSP and Takeda Announce Approval of the Marketing Authorization Application for Atypical Antipsychotic Agent Lurasidone in Switzerland
August 1, 2013
Transfer of Business of Takeda Bio Development Center to its Parent Company
July 31, 2013
Takeda Receives Marketing Authorization from China’s CFDA for New Type 2 Diabetes Therapy NESINA (alogliptin)
July 31, 2013
Agreement with Taisho for Distribution of Products of Biofermin and Transfer of a Part of Shares of Biofermin held by Takeda to Taisho
July 31, 2013
Takeda Announces Appointment of New Senior Leadership
July 30, 2013
NOVEL ORAL RHEUMATOID ARTHRITIS TREATMENT JAK INHIBITOR XELJANZ® LAUNCHED IN JAPAN
July 29, 2013
Takeda Receives Positive CHMP Opinion for Three New Type 2 Diabetes Therapies, VipidiaTM (alogliptin) and Fixed-Dose CombinationsVipdometTM (alogliptin-metformin) and IncresyncTM (alogliptin-pioglitazone)
July 26, 2013
Takeda Announces Unblinding of Phase 3 Study of Orteronel in Patients with Metastatic, Castration-Resistant Prostate Cancer That Progressed Post-Chemotherapy Based on Interim Analysis
July 19, 2013
Notice Concerning the Determination of the Items of Stock Options (Stock Acquisition Rights) for Members of the Board of Directors
July 19, 2013
Takeda Included in the FTSE4Good Global Index for the Ninth Consecutive Year
July 19, 2013
Takeda Announces Appointment of New Senior Leadership
July 18, 2013
Takeda and Zinfandel Pharmaceuticals Announce Results of a Study of the Performance Characteristics of a Genetics-Based Biomarker Risk Assignment Algorithm to Identify Risk of Mild Cognitive Impairment Due to Alzheimer’s Disease
July 10, 2013
Takeda Sets Terms and Conditions for its Domestic Unsecured Straight Bond Issues
July 1, 2013
Takeda Announces Withdrawal of Marketing Authorization Application for Peginesatide Injection in Europe
CLIPPED
Takeda isn’t quite in the top 10 among global drugmakers, but the company boasts the 7th-largest pipeline in the industry, according to its presentation at the conference. Yamada noted that 31% of the pipeline assets are in late-stage trials. Millennium is leading development of three late-stage contenders, TAK-700 for prostate cancer, MLN9708 for multiple myeloma and MLN0002 for ulcerative colitis andCrohn’s disease.
In an effort to revive its diabetes franchise, Takeda is in the final stage of development for a first-of-a-kind GPR40 agonist called TAK-875, designed to provide glucose-dependent insulin secretion.
With a rich late-stage pipeline at Takeda, Yamada wants the company to focus on growing its ranks of earlier-stage drug candidates. To do this the company has landed a variety of deals, including the purchase of Intellikine for $310 million to acquire anti-cancer drugs and more recently the acquisition of Envoy Therapeutics last year for $140 million.
Takeda has formed a New Frontier Science group to scout out the hottest research in academia and elsewhere and form collaborations with scientists behind those innovations. At the J.P. Morgan conference, Yamada said, he was attending many meetings with members of the biotech community.
Takeda Pharmaceutical Company Limited (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha?) is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company. The company has over 30,000 employees worldwide and achieved $16.2 billion USD in revenue during the 2012 fiscal year.[1] The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well asoncology through its independent subsidiary, Millennium: The Takeda Oncology Company.[2] Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo.[3][4] In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one the 100 best companies to work for in the United States.
Takeda Pharmaceuticals was founded on June 12, 1781 and was incorporated on January 29, 1925.
Takeda’s Japanese logo
In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals.[5]Through TAP Pharmaceuticals, Takeda and Abbott launched the blockbusters Lupron (leuprolide) in 1985 and Prevacid (lansoprazole) in 1995.
One of the firm’s mainstay drugs is Actos, a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. Launched in 1999, Actos has become the best-selling diabetes drug in the world with $4 billion USD in sales during the 2008 fiscal year.[6]
In February 2005, Takeda announced its acquisition of San Diego, California-based Syrrx, a company specializing in high-throughput X-ray crystallography, for $270 million.[7]
In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company’s pipeline candidates for the Japanese market.[8]
In March 2008, Takeda and Abbott Laboratories announced plans to conclude their 30-year old joint venture, TAP Pharmaceuticals, that had over $3 billion in sales in its final year. The split resulted in Abbott acquiring U.S. rights to Lupron and the drug’s support staff. On the other hand, Takeda received rights to Prevacid and TAP’s pipeline candidates. The move also increased Takeda’s headcount by 3,000 employees.[9]
In April 2008, Takeda announced that it was acquiring Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancerdrug research, for $8.8 billion. The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary, serving as the global center of excellence in oncology under its new name: “Millennium: The Takeda Oncology Company.” [10]
In May 2008, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.[11]
On May 19, 2011, Takeda Pharmaceutical and Nycomed announced that Takeda will acquire Nycomed for € 9.6 billion. The acquisition was completed by September 30, 2011.[12]
On April 11, 2012, Takeda Pharmaceutical and URL Pharma announced that Takeda will acquire URL Pharma for $800 million. The acquisition is expected to be completed within 60 days.
On 25 May 2012, Takeda announced the purchase of Brazilian pharmaceutical company Multilab by R$ 540 million.[13]
Takeda Midosuji Building, headquarters of Takeda Pharmaceutical Company, inChuo-ku, Osaka, Japan
Takeda operates two primary bases in Japan in Osaka and Tokyo. Its United States subsidiary is based in Deerfield, Illinois, and all Global Operations outside of Japan and U.S. are based in Opfikon (Zurich), Switzerland. The company maintains research & development sites in Osaka and Tsukuba, Japan; San Diego andSan Francisco, United States; Cambridge, United Kingdom; and Singapore.[14]
The company has manufacturing facilities in Japan, China, Indonesia, Italy, and Ireland.[15] Following the Nycomed acquisition, the Takeda manufacturing sites have been extended with facilities in Argentina,Austria,Belgium,Brazil,Denmark, Estonia,Germany,Mexico,Norway and Poland. Takeda has overseas marketing presences in the U.S., UK, France, Italy, Germany, Austria, Switzerland, Spain, China, Taiwan, Philippines, Thailand, Indonesia, and Singapore. It has recently[when?] announced its first foray into Canada, Portugal, Spain, Mexico, and Ireland.[15]
AT INDONESIA
Products
Some of the key products that Takeda produces on behalf of partners include:[16]
Actos (pioglitazone) - Type 2 Diabetes
Amitiza (lubiprostone) – Chronic idiopathic constipation
Basen (voglibose) – Type 2 Diabetes
Benet (risedronic acid) - Osteoporosis (Japan)
Blopress (candesartan) - Hypertension
Enbrel (etanercept) – Inflammatory diseases (Japan)
Dexilant (dexlansoprazole) - Gastroesophageal reflux disease - name changed to Dexilant in U.S.
Lupron/Leuplin (leuprorelin) – GnRH agonist for prostate cancer and endometriosis
Prevacid/Takepron (lansoprazole) – Gastroesophageal reflux disease
Rozerem (ramelteon) - Insomnia
Uloric (febuxostat) - Gout
Velcade (bortezomib) - Multiple myeloma and mantle cell lymphoma (Millennium Pharmaceuticals)
AT UK
References
“Financial Results for Fiscal 2012″ (PDF). Takeda Pharmaceutical Company Limited. May 9, 2013. Retrieved June 13, 2013.
“Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes”. Newsblaze.com. 2009-08-28. Retrieved 2010-09-18.
”FAQ.” Takeda Pharmaceutical Company. Retrieved on February 2, 2011. “Q : Where is Takeda located? A : The Head Office is located in Osaka, Japan, and the Tokyo Head Office is located in Tokyo, Japan.”
”Overview.” Takeda Pharmaceutical Company. Retrieved on February 2, 2011. “Headquarters Head Office 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645″ and “Tokyo Head Office 12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-8668″
“TAP Pharmaceutical Products, Inc.: Private Company Information – BusinessWeek”. Investing.businessweek.com. 2008-04-30. Retrieved 2010-09-18.
Decker, Susan (2009-07-06). “Takeda Sues Torrent to Stop Generic Copy of Actos Diabetes Pill”. Bloomberg. Retrieved 2010-09-18.
Somers, Terri (2005-02-08). “Japanese drug giant taking over Syrrx here | The San Diego Union-Tribune”. Signonsandiego.com. Retrieved 2010-09-18.
“Takeda, Amgen in exclusive tie-up for Japanese market”. MarketWatch. 2008-02-04. Retrieved 2010-09-18.
Marrazzo, Amanda (2008-05-15). “Featured Articles From The Chicago Tribune”. Archives.chicagotribune.com. Retrieved 2010-09-18.
“MILLENNIUM: The Takeda Oncology Company | About Millennium | Our History”. Mlnm.com. Retrieved 2010-09-18.
staff (2008-06-15). “Takeda Signs On as Alnylam’s Asian Partner for $150M Upfront”. Genetic Engineering & Biotechnology News (print) (Mary Ann Liebert, Inc.). p. 14.
http://www.takeda.com/press/article_43116.html
Hirschler, Ben (May 25, 2012). “Farmacêutica Takeda comprará Multilab por até R$ 540 mi”. Grupo Abril (in portuguese). Exame. Retrieved January 27, 2013.
“Locations | Worldwide | Takeda Pharmaceutical Company Limited”. Takedaism.com. Retrieved 2010-09-18.
“By Business | Worldwide | Takeda Pharmaceutical Company Limited”. Takedaism.com. Retrieved 2010-09-18.
“Annual Reports | Investor Information | Takeda Pharmaceutical Company Limited”. Takeda.com. Retrieved 2010-09-18.
Takeda Pharmaceutical Company
Wall Street Journal article on Takeda
Takeda Pharmaceutical Company Limited
Native name
武田薬品工業株式会社
Type
Public KK
Traded as
TYO: 4502
OTC Pink: TKPYY
Industry
Pharmaceuticals
Founded
Doshomachi, Osaka, Japan (June 12, 1781)
Headquarters
1-1, Doshomachi Yonchome,Chuo-ku, Osaka, Japan
Key people
Yasuchika Hasegawa (President & CEO)
Revenue
¥1,557,267 million (FY2012)[* 1]
Operating income
¥122,505 million (FY 2012)[* 1]
Net income
¥131,244 million (FY 2012)[* 1]
Total assets
¥3,955,599 million (FY 2012)[* 1]
Total equity
¥2,223,359 million (FY 2012)[* 1]
Employees
30,481 (2012)
Website
takeda.com (Global website)
References:
“Financial Results for Fiscal 2012″ (PDF). Takeda Pharmaceutical Company Limited. May 9, 2013. Retrieved June 13, 2013.
CMC CENTRE
The Chemistry, Manufacturing and Controls (CMC) Center is a global organization responsible for overall R&D activities ranging from chemical information on development candidates to the processes leading to “manufacturing” of pharmaceutical products.
The main sites are located in Osaka and consist of the following laboratories: the Chemical Development Laboratories in charge of R&D for developing the manufacturing methods of active pharmaceutical ingredients and the manufacturing of drug substances for clinical samples; the Pharmaceutical Technology R&D Laboratories in charge of R&D for dosage forms, manufacturing and packaging, as well as manufacturing of clinical samples; and the Analytical Development Laboratories in charge of R&D for the development of analytical methods and stability studies of clinical samples. In addition, Hikari Bio-Manufacturing Technology Laboratories is located in Hikari (Yamaguchi) and this is where antibody drug substances are manufactured.
As for overseas sites, the Cambridge Biologics CMC Group (Massachusetts) and the Chicago Pharmaceutical Science Group (Illinois) are located in the USA, while the CMC Center Europe is mainly located in Roskilde, Denmark. All research and development activities at Takeda are promoted with the cooperation of these sites.
List of Publications of Takeda Research Laboratories
2012 Download Entire File
PDF 0.4MB 34P
2011 Download Entire File
PDF 0.5MB 26P
2010 Download Entire File
PDF 0.5MB 16P
2009 Download Entire File
PDF 0.5MB 16P
2008 Download Entire File
PDF 0.1MB 17P
2007 Download Entire File
PDF 0.1MB 15P
2006 Download Entire File
PDF 0.1MB 17P
Filed under: COMPANIES, Japan marketing, Japan pipeline, Uncategorized Tagged: TAKEDA